GLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY
16 Mai 2024 - 2:30PM
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical device company focused on the design, development, and
commercialization of novel technologies for people with diabetes,
today announced that its implantable continuous glucose monitor has
successfully completed 30 days of a 60-day long-term preclinical
study on measuring glucose in the epidural space.
The Glucotrack sensor, implanted in the epidural
space of animals, closely tracked both blood glucose and a
commercially available subcutaneous continuous glucose monitor
(CGM) throughout the 30-day period. The implantation procedure took
approximately 20 minutes, and the animals recovered without
complications. No abnormal clinical signs or findings in the spinal
cord or surrounding tissues were observed.
“We are excited by the performance of our
epidural glucose sensor in this long-term study, which builds on
the encouraging results from our acute testing,” said Paul V.
Goode, PhD, CEO of Glucotrack. “We are proud to be at the forefront
of developing this exciting technology, which has the potential to
benefit millions of people with diabetes.”
The 60-day long-term study is ongoing, with
periodic glucose tolerance testing to compare the performance of
the Glucotrack epidural sensor performance against blood glucose
and subcutaneous CGM.
Glucotrack previously announced that it had
completed preclinical animal testing in an acute setting and had
initiated this long-term animal study to assess sustained epidural
glucose monitoring performance. While the acute study demonstrated
feasibility of accurately measuring glucose in the epidural space
over several hours, this long-term study assesses the durability of
the epidural glucose sensor measurement over a significantly longer
duration of monitoring.
Painful diabetic neuropathy is a progressive
neurological disorder that affects approximately one-fifth of the
more than 38 million Americans with diabetes, equating to more than
7 million individuals.1,2 The Company believes that, if approved, a
continuous glucose monitoring system that takes readings in the
spinal epidural space may be integrated with existing treatments
for these patients, simplifying their device and disease
management.
For more information about Glucotrack, visit
glucotrack.com. Information on the Company’s website does not
constitute a part of and is not incorporated by reference into this
press release.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on
the design, development, and commercialization of novel
technologies for people with diabetes. The Company is currently
developing a long-term implantable continuous blood glucose
monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable
system that continually measures blood glucose levels with a sensor
longevity of 2+ years, no on-body wearable component and with
minimal calibration. For more information, please
visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “believe”, “expect”, “plan” and “will” are
intended to identify forward-looking statements. Such
forward-looking statements are based on the beliefs of management,
as well as assumptions made by, and information currently available
to, management. These statements relate only to events as of the
date on which the statements are made, and Glucotrack undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law. All of the forward-looking statements
made in this press release are qualified by these cautionary
statements, and there can be no assurance that the actual results
anticipated by Glucotrack will be realized or, even if
substantially realized, that they will have the expected
consequences to or effects on us or our business or operations.
Readers are cautioned that certain important factors may affect
Glucotrack’s actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect Glucotrack’s results
include, but are not limited to, the ability of Glucotrack to raise
additional capital to finance its operations (whether through
public or private equity offerings, debt financings, strategic
collaborations or otherwise); risks relating to the receipt (and
timing) of regulatory approvals (including U.S. Food and Drug
Administration approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to
Glucotrack’s future distribution agreements; risks relating to its
ability to hire and retain qualified personnel, including sales and
distribution personnel; and the additional risk factors described
in Glucotrack’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including its Annual Report on Form 10-K
for the year ended December 31, 2023 as filed with the SEC on March
28, 2024.
Contacts:
Investor Relations:investors@glucotrack.com
Media:GlucotrackPR@icrinc.com
1 Abbott CA, Malik RA, van Ross ER, Kulkarni J,
Boulton AJ. Prevalence and characteristics of painful diabetic
neuropathy in a large community-based diabetic population in the
U.K. Diabetes Care 2011;34:2220–2224.2 Centers for Disease Control
and Prevention. (2022). National Diabetes Statistics Report
website.
https://www.cdc.gov/diabetes/data/statistics-report/index.html
GlucoTrack (NASDAQ:GCTK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
GlucoTrack (NASDAQ:GCTK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024